Drugs for Hyperinsulinemic Hypoglycemia, Familial, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 46)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
lanreotide |
Approved |
Phase 4 |
|
108736-35-2 |
|
Synonyms:
|
2 |
|
Angiopeptin |
|
Phase 4 |
|
|
|
3 |
|
Diazoxide |
Approved |
Phase 2 |
|
364-98-7 |
3019 |
Synonyms:
2H-1,2, 4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
2H-1,2,4-Benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
364-98-7
7-Chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide
7-Chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
7-chloro-3-methyl-4H-1
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido
7-Cloro-3-metil-2H-1,2,4-benzotiodiazina-1,1-diossido [Italian]
AC1L1EZN
Aroglycem
Bio1_000036
Bio1_000525
Bio1_001014
Bio2_000027
Bio2_000507
BPBio1_000016
BRD-K73109821-001-05-2
BSPBio_000014
BSPBio_001307
BSPBio_002290
C06949
C8H7ClN2O2S
CAS-364-98-7
CBiol_001750
CHEBI:4495
CHEMBL181
CID3019
CPD000058392
D 9035
D00294
D003981
D9035_SIGMA
DB01119
Diazossido
Diazossido [DCIT]
Diazossido [Italian]
diazoxide
Diazoxide
Diazoxide (JAN/USP/INN)
Diazoxide [USAN:INN:BAN]
Diazoxido
Diazoxido [INN-Spanish]
Diazoxidum
Diazoxidum [INN-Latin]
Dizoxide
EINECS 206-668-1
EU-0100404
Eudemine
HMS1361B09
HMS1568A16
HMS1791B09
HMS1922L22
HMS1989B09
HMS2051P20
HMS2089L04
HMS2093N12
Hyperstat
Hyperstat (TN)
Hypertonalum
I06-2041
|
IDI1_033777
KBio2_000027
KBio2_002595
KBio2_005163
KBio3_000053
KBio3_000054
KBio3_001510
KBioGR_000027
KBioGR_001776
KBioSS_000027
Lopac0_000404
Lopac-D-9035
LS-40410
MLS000028459
MLS001076071
MolPort-003-666-772
MolPort-003-941-186
Mutabase
NCGC00015380-01
NCGC00015380-02
NCGC00015380-03
NCGC00015380-05
NCGC00015380-12
NCGC00024907-01
NCGC00024907-02
NCGC00024907-03
NCGC00024907-04
NCGC00024907-05
NCGC00024907-06
NCGC00024907-07
NCGC00024907-08
nchembio.150-comp49
nchembio.476-comp10
NSC 64198
NSC 76130
NSC64198
NSC-64198
NSC76130
Prestwick_163
Prestwick0_000087
Prestwick1_000087
Prestwick2_000087
Prestwick3_000087
Proglicem
Proglycem
SAM001246872
Sch 6783
Sch-6783
SMR000058392
SPBio_001953
SPECTRUM2300206
Spectrum3_000735
Spectrum4_001248
SRG 95213
SRG-95213
Tocris-0964
UNII-O5CB12L4FN
VU0239714-6
ZINC03872277
|
|
4 |
|
Pancrelipase |
Approved, Investigational |
Phase 2 |
|
53608-75-6 |
|
Synonyms:
lipase
Pancrealipase
Pancreatic extract pancrelipase
Pancreatic protease
|
Pancreatin
Pancreatinum
Pancrelipase (amylase
protease)
|
|
5 |
|
Exenatide |
Approved, Investigational |
Phase 1, Phase 2 |
|
141758-74-9 |
15991534 |
Synonyms:
141732-76-5
141758-74-9
286014-72-0
335149-21-8
AC 2993
AC 2993 LAR
AC 2993A
Byetta
C074031
CHEBI:490990
CHEMBL414357
Ex4 peptide
|
Exenatida
Exenatide
Exenatide synthetic
Exenatide Synthetic
Exendin 4
Exendin 4 (Heloderma suspectum)
Exendin-4
Extendin-4
LY2148568
Synthetic exendin-4
UNII-9P1872D4OL
|
|
6 |
|
Glucagon |
Approved |
Phase 1, Phase 2 |
|
16941-32-5 |
|
Synonyms:
Glucagon
Glucagon (recombinant dna origin)
Glucagon recombinant
Glucagon, human
|
Glucagon, porcine
Glucagone
Glucagonum
|
|
7 |
|
tannic acid |
Approved |
Phase 1, Phase 2 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
8 |
|
Benzocaine |
Approved, Investigational |
Phase 1, Phase 2 |
|
94-09-7, 1994-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
|
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
9 |
|
pancreatin |
|
Phase 2 |
|
|
|
10 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
11 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2 |
|
|
|
12 |
|
Anti-Obesity Agents |
|
Phase 1, Phase 2 |
|
|
|
13 |
|
Polygeline |
|
Phase 1, Phase 2 |
|
|
|
14 |
|
lysine |
|
Phase 1, Phase 2 |
|
|
|
15 |
|
Radiopharmaceuticals |
|
Phase 1, Phase 2 |
|
|
|
16 |
|
Plasma Substitutes |
|
Phase 1, Phase 2 |
|
|
|
17 |
|
Blood Substitutes |
|
Phase 1, Phase 2 |
|
|
|
18 |
|
Glucagon-Like Peptide 1 |
|
Phase 1, Phase 2 |
|
|
|
19 |
|
Acarbose |
Approved, Investigational |
Phase 1 |
|
56180-94-0 |
441184 |
Synonyms:
(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4S,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
(3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino]oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol
1,4-DEOXY-4-((5-HYDROXYMETHYL-2,3,4-TRIHYDROXYCYCLOHEX-5,6-ENYL)AMINO)FRUCTOSE
1agm
1gah
1k1y
1lf9
1ukt
4,6-dideoxy-4-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucopyranose
4,6-dideoxy-4-{[(1S,4S,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}-alpha-D-glucopyranosyl-(1->4)-alpha-D-glucopyranosyl-(1->4)-D-glucose
56180-94-0
AC1L26GM
AC1L9APL
AC1L9G0J
AC1L9HYX
AC1NAU1X
AC1OCEJZ
Acarbosa
Acarbosa [INN-Spanish]
acarbose
Acarbose
Acarbose (JAN/USAN/INN)
Acarbose [USAN:BAN:INN:JAN]
Acarbosum
Acarbosum [INN-Latin]
ACI-(1-4)GLD-(1-4)GLC-(1-4)GLB
ACR
Alpha-Acarbose
Bay g 5421
Bayer brand OF acarbose
BAY-g 5421
Bay-g-5421
BB_NC-1311
Beta-Acarbose
C06802
C25H43NO18
CHEBI:2376
CHEBI:506767
CHEMBL1566
CHEMBL394434
|
CHEMBL569486
CID10627975
CID41774
CID441184
CID4432690
CID444254
CID445421
CPD000466376
D00216
DB00284
EINECS 260-030-7
Glucobay
Glucor
Glumida
HMC-(1-4)AGL-(1-4)GLC-(1-4)GLC
HMS2051F03
HMS2093I22
Lasa brand OF acarbose
LS-71702
MLS000759506
MLS001424056
MolPort-002-507-369
MolPort-003-844-373
NCGC00096061-01
NCGC00096061-02
NCGC00160515-01
O-4,6-Dideoxy-4-(((1S-(1alpha,4alpha,5beta,6alpha))-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose
O-4,6-Dideoxy-4-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1->4)-O-alpha-D-glucopyranosyl-(1->4)-D-glucose
O-4,6-Dideoxy-4-(((1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl)amino)-alpha-D-glucopyranosyl-(1-4)-O-alpha-D-glucopyranosyl-(1-4)-D-glucose
Prandase
Prandase, Precose, Glucobay, Bay-g 5421, Acarbose
Precose
Precose (TN)
QPS
S1271_Selleck
SAM001246733
SMR000466376
SPECTRUM1505172
STK801930
UNII-T58MSI464G
|
|
20 |
|
Octreotide |
Approved, Investigational |
Phase 1 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
Compound 201 995
Compound 201995
Compound 201-995
D00442
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
DRG-0115
HMS2090C09
HS-2020
L000453
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
|
Longastatin
LS-177735
LS-187135
NCGC00181796-01
nchembio.184-comp3
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide acetate salt
Octreotide Acetate Salt
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
Sandostatin
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SM 201-995
SMS 201-995
SMS-201-995
UNII-RWM8CCW8GP
zacycloicosane-4-carboxamide acetate
|
|
21 |
|
Somatostatin |
Approved, Investigational |
Phase 1 |
|
38916-34-6, 51110-01-1 |
53481605 |
Synonyms:
Growth hormone-inhibiting hormone (ghih)
Somatostatin
Somatostatina
Somatostatine
Somatostatinum
|
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
Synthetic growth hormone release-inhibiting hormone
Synthetic somatostatin-14
|
|
22 |
|
Levodopa |
Approved |
Phase 1 |
|
59-92-7 |
6047 |
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(−)-dopa
(-)-Dopa
(2S)-2-amino-3-(3,4-Dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(2S)-2-amino-3-(3,4-Dihydroxyphenyl)propanoic acid
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
23734-74-9
25525-15-9
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
3 Hydroxy L tyrosine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-dihydroxy-L-phenylalanine
3,4-Dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxyphenylalanine (VAN)
3,4-Dihydroxyphenyl-L-alanine
34241-25-3
37830_FLUKA
3-Hydroxy-L-tyrosine
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
b-(3,4-Dihydroxyphenyl)-L-alanine
Bendopa
beta-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
BIDD:GT0158
Bio-0575
Biodopa
bmse000322
BPBio1_000059
Brocadopa
BSPBio_000053
BSPBio_002354
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
Cerepap
CHEBI:15765
CHEMBL1009
CID6047
Cidandopa
component of Sinemet
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
DOPA
Dopaflex
Dopaidan
Dopal
Dopal-fher
Dopal-Fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
Eldopal
Eldopar
Eldopatec
EU-0100454
Eurodopa
Helfo DOPA
|
helfo-Dopa
Helfo-Dopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
IDI1_000452
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
IV Levodopa
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L 3,4 Dihydroxyphenylalanine
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
l)-L-alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-(3,4-Dihydroxyphenyl)-alanine
L-3,4-dihydroxyphenylalanine
L-3,4-Dihydroxyphenylalanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
Laradopa
Larodopa
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-b-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
L-O-Dihydroxyphenylalanine
L-o-Hydroxytyrosine
Lopac0_000454
Lopac-D-9628
LS-255
L-β-(3,4-dihydroxyphenyl)alanine
Maipedopa
medphano Brand OF levodopa
MLS000028514
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
nchembio.2007.55-comp26
nchembio.89-comp9
ne
NINDS_000452
NSC 118381
NSC118381
Parda
Pardopa
PDSP1_001541
PDSP2_001525
Prestwick_185
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prodopa
Ro 4-6316
Roberts brand OF levodopa
Roche brand OF levodopa
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
Sobiodopa
SPBio_000391
SPBio_001974
Spectrum_000454
Spectrum2_000496
SPECTRUM2300205
Spectrum4_000539
Spectrum5_001899
Syndopa
UNII-46627O600J
Veldopa
Weldopa
β-(3,4-dihydroxyphenyl)alanine
β-(3,4-dihydroxyphenyl)-L-alanine
|
|
23 |
|
Lactitol |
Approved, Investigational |
Phase 1 |
|
585-88-6, 585-86-4 |
493591 |
Synonyms:
(2S,3R,4R,5R)-4-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}hexane-1,2,3,5,6-pentol
4-O-a-D-Glucopyranosyl-D-glucitol
4-O-alpha-delta-Glucopyranosyl-delta-glucitol
4-O-alpha-D-Glucopyranosyl-D-glucitol
4-O-α-D-glucopyranosyl-D-glucitol
a-D-GLC-(1->4)-D-GLC-ol
a-D-GLCP-(1->4)-D-GLC-ol
a-D-Glucosyl-(1->4)-D-glucitol
alpha-D-GLC-(1->4)-D-GLC-ol
alpha-D-GLCP-(1->4)-D-GLC-ol
alpha-D-Glucosyl-(1->4)-D-glucitol
Amalti syrup
Amalty MR 100
|
D-4-O-alpha-D-Glucopyranosylglucitol
delta-4-O-alpha-delta-Glucopyranosylglucitol
delta-Maltitol
D-Maltitol
Lactitol
Lactitolum
Malbit
Malti MR
Maltisorb
Maltit
α-D-GLC-(1->4)-D-GLC-ol
α-D-GLCP-(1->4)-D-GLC-ol
α-D-glucosyl-(1->4)-D-glucitol
|
|
24 |
|
Cardiac Glycosides |
|
Phase 1 |
|
|
|
25 |
|
Glycoside Hydrolase Inhibitors |
|
Phase 1 |
|
|
|
26 |
|
Incretins |
|
Phase 1 |
|
|
|
27 |
|
Insulin, Globin Zinc |
|
Phase 1 |
|
|
|
28 |
|
insulin |
|
Phase 1 |
|
|
|
29 |
|
Insulin aspart |
Approved |
|
|
116094-23-6 |
16132418 |
Synonyms:
(AspB28)-human insulin
1024611-56-0
116094-23-6
139532-40-4
28(sup B)-L-Aspartic acid-insulin (human)
877034-90-7
Aspart
Aspart insulin
Aspart Insulin
AspB28-insulin (human)
B28-Aspart-Insulin
B28-Asp-insulin
INA-X 14
Insulin aspart
Insulin aspart [USAN]
|
Insulin aspart protamine
Insulin aspart protamine recombinant
Insulin aspart recombinant
Insulin X14
Insulin, aspart protamine, human
Insulin, aspart, human
Insulin,aspart protamine
Insulina asparta
LS-185932
NovoLog
Novolog mix 70/30
NovoMix 30
NovoRapid
NovoRapid 30 Mix
UNII-D933668QVX
|
|
30 |
|
Tocopherol |
Approved, Investigational |
|
|
1406-66-2, 54-28-4 |
14986 |
Synonyms:
3,4-dihydro-2,7,8-Trimethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-ol
7,8-Dimethyltocol
7,8-dimethyltocolo-Xylotocopherol
Abortosan
adisseo Brand OF tocopherol
Alcala brand OF tocopherol acetate
Aliud brand OF tocopherol
Antioxidans e-hevert
Aquasol e
Arkopharma brand OF tocopherol acetate
AstraZeneca brand OF tocopherol acetate
Atarost brand OF tocopherol acetate
Ausrichter brand OF tocopherol
Auxina e
Balkanpharma brand OF tocopherol
Bayer brand OF tocopherol acetate
bio e
Biocur brand OF tocopherol acetate
biopto-e
Biosan
Bioweyxin
Blackmores brand OF tocopherol
Bottger brand OF tocopherol acetate
Cambridge laboratories brand OF tocopherol actetate
Dal e
Dal vita brand OF vitamin e succinate
Dal-e
Dal-vita brand OF vitamin e succinate
Davitamon
Dermorelle
Detulin
D-gamma-Tocopherol
DL-alpha-Tocopherol
DL-a-Tocopherol
DL-α-tocopherol
Dragees, vitamin-e
e Ferol
e Mulsin
e Vicotrat
e Vitamin e
Ecoro
e-Ferol
Elex verla
Embial
e-Mulsin
Ephynal
Eplonat
Equivit e
Eu rho brand OF tocopherol
EUNOVA vitamin e
Eusovit
e-Vicotrat
EVI-mirale, vitamin-e
Evion
e-Vitamin-ratiopharm
GNR Pharma brand OF tocopherol actetate
GNR-Pharma brand OF tocopherol actetate
Grace brand OF tocopherol
Grunwalder brand OF tocopherol
g-Tocopherol
Hervert brand OF tocopherol acetate
Heyl brand OF tocopherol acetate
Hydrovit e
ICN brand OF tocopherol acetate
Infirmarius rovit brand OF tocopherol
Infirmarius-rovit brand OF tocopherol
Internation animal health brand OF tocopherol acetate
Jenapharm brand OF tocopherol
Kentucky brand OF tocopherol
Kohler brand OF tocopherol
Lasar
Malton e
medphano Brand OF tocopherol acetate
Merck brand OF tocopherol acetate
Methyltocols
Micorvit e
MIP brand OF tocopherol acetate
Mowivit vitamin e
Mucos brand OF tocopherol acetate
Organon brand OF tocopherol acetate
O-Xylotocopherol
puncto e
Ratiopharm brand OF tocopherol
Richelet brand OF tocopherol acetate
|
Richtavit e
Riemser brand OF tocopherol
Roche nicholas brand OF tocopherol acetate
Rodisma med brand OF tocopherol
Rodisma-med brand OF tocopherol
Sanavitan S
Sanum kehlbeck brand OF tocopherol actetate
Sanum-kehlbeck brand OF tocopherol actetate
Schwarzhaupt brand OF tocopherol acetate
Sciencex brand OF tocopherol acetate
Scot tussin brand OF tocopherol acetate
Scot-tussin brand OF tocopherol acetate
Snow-e muscle, energy and feritility
Spondyvit
Stadapharm brand OF tocopherol
Steigerwald brand OF tocopherol acetate
Strathmann brand OF tocopherol
tocoferol
tocoferoles
Tocolion
Tocopa
Tocopharm
Tocopherol
tocophérol
Tocopherol ausrichter brand
Tocopherol balkanpharma brand
Tocopherol bayer
Tocopherol grace brand
Tocopherol grunwalder brand
Tocopherol infirmarius-rovit brand
Tocopherol kentucky brand
Tocopherol ratiopharm brand
Tocopherol rodisma-med brand
Tocopherol stadapharm brand
Tocopherol togal brand
Tocopherol twardy brand
Tocopherol verla brand
Tocopherol wiedemann brand
Tocopherol worwag brand
Tocopherols
Tocovital
Togal brand OF tocopherol
Togasan vitamin e
Troyapharm brand OF tocopherol acetate
Twardy brand OF tocopherol
Unique e
uno Vit
uno-Vit
UnoVit
Verla brand OF tocopherol
Veyx brand OF tocopherol
Vibolex
Vit e hydrosol
Vit. e stada
Vita e
Vita plus e
Vita-e
VitaE
Vitagutt vitamin e
Vitamin e al
Vitamin e dragees
Vitamin e evi mirale
Vitamin e gamma
Vitamin e MP
Vitamin e natur
Vitamin e sanum
Vitamin e suspension
Vitamin e, mowivit
Vitamin e, togasan
Vitamin e, vitagutt
Vitamin emp
Vitamin e-MP
Vitamin-e dragees
Vitamine e GNR
Vitamin-e evi-mirale
Vita-plus e
VitaPlus e
Vitazell
Wiedemann brand OF tocopherol
Wiedemann brand OF vitamin e succinate
Woelm brand OF tocopherol acetate
Worwag brand OF tocopherol
γ-tocopherol
|
|
31 |
|
Dopamine |
Approved |
|
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
32 |
|
Vitamin E |
Approved, Nutraceutical, Vet_approved |
|
|
59-02-9 |
14985 |
Synonyms:
(+)-alpha-Tocopherol
(+)-a-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-dihydro-2,5,7,8-Tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'r,8'r)-alpha-Tocopherol
(2R,4'r,8'r)-a-Tocopherol
(2R,4'r,8'r)-α-tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-trimethyltocol
5,7,8-Trimethyltocol
a-D-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
alpha-Tocopherol
Amino-Opti-E
Aquasol E
a-Tocopherol
D-alpha-Tocopherol
|
Daltose
D-a-Tocopherol
delta-alpha-Tocopherol
Denamone
d-α-tocopherol
D-α-tocopherol
E-200 I.U. Softgels
E-Complex-600
E-Ferol
Eprolin
E-Vitamin succinate
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-Tocopherol
RRR-alpha-Tocopheryl
Tocopherol
Vitamin e
Vitamin ea
Vitamin Plus E Softgells
Vitec
α-tocopherol
|
|
33 |
|
Tocotrienol |
Investigational |
|
|
6829-55-6 |
|
34 |
|
Micronutrients |
|
|
|
|
|
35 |
|
Trace Elements |
|
|
|
|
|
36 |
|
Vitamins |
|
|
|
|
|
37 |
|
Antioxidants |
|
|
|
|
|
38 |
|
Nutrients |
|
|
|
|
|
39 |
|
Protective Agents |
|
|
|
|
|
40 |
|
Tocotrienols |
|
|
|
|
|
41 |
|
Tocopherols |
|
|
|
|
|
42 |
|
Dihydroxyphenylalanine |
|
|
|
|
|
43 |
|
Neurotransmitter Agents |
|
|
|
|
|
44 |
|
Dopamine Agents |
|
|
|
|
|
45 |
|
Fluorides |
|
|
|
|
|
46 |
|
Hypoglycemic Agents |
|
|
|
|
|
Interventional clinical trials:
(show all 35)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Treatment With Lanreotide Autogel (Somatostatin Analogue) in Patients With Congenital Hyperinsulinism of Infancy Already Treated With Somatostatin Analog by Pump |
Unknown status |
NCT01070758 |
Phase 4 |
Lanreotide autogel |
2 |
A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism |
Recruiting |
NCT03777176 |
Phase 3 |
dasiglucagon |
3 |
A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism |
Recruiting |
NCT04172441 |
Phase 2, Phase 3 |
dasiglucagon;Placebo |
4 |
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety |
Recruiting |
NCT03042416 |
Phase 3 |
18F-DOPA |
5 |
An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism |
Enrolling by invitation |
NCT03941236 |
Phase 3 |
dasiglucagon |
6 |
A Phase II Safety and Efficacy Study of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Children With Hyperinsulinemic Hypoglycemia |
Completed |
NCT01468454 |
Phase 2 |
18 F-DOPA |
7 |
Localization of Focal Forms of Hyperinsulinism of Infancy With 18F-labeled L-fluoro-DOPA PET Scan |
Completed |
NCT00674440 |
Phase 2 |
F-DOPA |
8 |
An Open Label Pilot Study of the Effects of the Glucagon-like Peptide-1 Receptor Antagonist, Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism |
Completed |
NCT00571324 |
Phase 1, Phase 2 |
Exendin-(9-39) |
9 |
A Phase 2 Proof-of-Concept Study of CSI-Glucagonâ„¢ (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism |
Completed |
NCT02937558 |
Phase 2 |
Glucagon |
10 |
Replace Sandostatine® in Three Daily Subcutaneous Injections by a Single Intramuscular Injection of Sandostatine® LP Per Month in Patients With a Diffuse Form of Hyperinsulinism |
Completed |
NCT00987168 |
Phase 2 |
Sandostatine LP |
11 |
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism (HI) |
Completed |
NCT02604485 |
Phase 2 |
Cohort 1;Cohort 2;Cohort 3;Cohort 4 |
12 |
Role of GLP-1 in Congenital Hyperinsulinism:Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity |
Completed |
NCT00897676 |
Phase 1, Phase 2 |
Exendin-(9-39);placebo |
13 |
Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass |
Completed |
NCT03984370 |
Phase 2 |
ZP4207 |
14 |
A Phase 2, Interventional, Randomized, Double-Blind, Placebo-Controlled Pilot Study of Glucagon RTU in Subjects Who Experience Hyperinsulinemic Hypoglycemia After Bariatric Surgery |
Completed |
NCT03770637 |
Phase 2 |
Glucagon RTU |
15 |
Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 Uptake in the Kidney |
Completed |
NCT02541734 |
Phase 1, Phase 2 |
Gelofusine;Placebo |
16 |
Role of Glucagon-Like Peptide-1 (GLP-1) in Congenital Hyperinsulinism: Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia |
Terminated |
NCT00835328 |
Phase 1, Phase 2 |
Exendin (9-39);Vehicle |
17 |
Pasireotide for Prevention of Hypoglycemia in Patients With Hyperinsulinemic Hypoglycemia |
Withdrawn |
NCT03053284 |
Phase 2 |
Pasireotide 0.6Mg Solution for Injection;Saline Solution |
18 |
Pilot Study of the Efficacy and Safety of Sirolimus in the Treatment of Congenital Hyperinsulinism. |
Withdrawn |
NCT02524639 |
Phase 1, Phase 2 |
Sirolimus |
19 |
A Pilot Study Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Post-RYGB |
Completed |
NCT02685852 |
Phase 1 |
Exenatide;Acarbose;Placebo |
20 |
18F-Fluoro-L- DOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism |
Recruiting |
NCT04205604 |
Phase 1 |
|
21 |
The Use of Fluorodopa F 18 Positron Emission Tomography Combined With Computed Tomography in Congenital Hyperinsulinism and Insulinoma |
Recruiting |
NCT02021604 |
Phase 1 |
Fluorodopa F 18 |
22 |
Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia |
Recruiting |
NCT03103009 |
Phase 1 |
Pasireotide |
23 |
Long Term Glucose Metabolism in Conservatively Treated Patients With Congenital Hyperinsulinism |
Unknown status |
NCT01819584 |
|
|
24 |
Towards Individualized Surgery in Non-focal Congenital Hyperinsulinism |
Completed |
NCT02108730 |
|
|
25 |
New Imaging Procedure for the Localisation of Insulinoma |
Completed |
NCT02127541 |
|
|
26 |
Bihormonal Bionic Pancreas for the Treatment of Diabetes Post-Pancreatectomy in Children With Congenital Hyperinsulinism - A Pilot Study |
Completed |
NCT03303196 |
|
|
27 |
Prevention of Hypoglycemia in Patients With Post-Gastric Bypass Hyperinsulinemic Hypoglycemia |
Completed |
NCT01933490 |
|
|
28 |
The Physiology of Glucagon-like-peptide-1 Espression in Patients With Endogenous Hyperinsulinism: Correlation With Histopathology |
Recruiting |
NCT03768518 |
|
|
29 |
Application of Raw Corn Starch on Patients With Unoperated Insulinoma is Helpful to Decrease Risk of Hypoglycemia |
Recruiting |
NCT03930368 |
|
|
30 |
Vitamin E Supplementation in Hyperinsulinism/Hyperammonemia Syndrome |
Active, not recruiting |
NCT03797222 |
|
|
31 |
Compassionate Use of SOM230 for Individual Patient (NS, 14-Jan-1986) With Hyperinsulinemic/Hypoglycemia |
Available |
NCT02835131 |
|
Pasireotide |
32 |
Expanded Access Use of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia |
Available |
NCT01916148 |
|
18F-DOPA |
33 |
Phase II Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia |
Available |
NCT02533219 |
|
18 F-DOPA |
34 |
Deciphering the Enigma of Postprandial Hyperinsulinaemic Hypoglycaemia After Bariatric Surgery, Part 1 C: Effect of Postprandial Hypoglycaemia on Driving Performance. |
Not yet recruiting |
NCT04330196 |
|
|
35 |
Deciphering the Enigma of Postprandial Hyperinsulinaemic Hypoglycaemia After Bariatric Surgery Part 1 B: Evaluation of the Neuro-endocrine Response to Hypoglycaemia. |
Not yet recruiting |
NCT04334161 |
|
|
|